Market revenue in 2024 | USD 280.0 million |
Market revenue in 2030 | USD 485.6 million |
Growth rate | 9.8% (CAGR from 2025 to 2030) |
Largest segment | Continuous blood glucose monitoring system |
Fastest growing segment | Smart insulin pens |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Smart glucose meter, Continuous blood glucose monitoring system, Smart insulin pens, Smart Insulin Pumps/Closed Loop Systems, Apps |
Key market players worldwide | Abbott Laboratories, Medtronic PLC, Roche Holding AG ADR, Bayer AG, Sanofi SA, DexCom Inc, Insulet Corp, PHC Holdings Corp, B. Braun Medical, Brigade High Income Founders |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to digital diabetes management market will help companies and investors design strategic landscapes.
Continuous blood glucose monitoring system was the largest segment with a revenue share of 43.82% in 2024. Horizon Databook has segmented the Australia digital diabetes management market based on smart glucose meter, continuous blood glucose monitoring system, smart insulin pens, smart insulin pumps/closed loop systems, apps covering the revenue growth of each sub-segment from 2018 to 2030.
According to the Australian Bureau of Statistics, there were an estimated 1.2 million people living with diabetes in 2017. Several government initiatives are expected to propel the market over the forecast period. For instance, the Australian National Diabetes Strategy 2016-2020 was formed to outline Australia’s national response to diabetes and the utilization of existing limited resources in a better way.
Furthermore, the Australian government is subsidizing CGM products for diabetes patients across Australia. In 2016, the Federal election in the Government of Australia committed to subsidizing CGM technology to assist young adults and children under 21 years of age who are suffering from type 1 diabetes.
Diabetes Australia now provides access to subsidized CGM products through the National Diabetes Service Schemes (NDSS). The market is further propelled by technological advancements in diabetes devices in the region. Currently, Dexcom G5, Minimed 640, Medtronic 670G, and Guardian Connect CGM systems are some of the key products available in the market.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia digital diabetes management market, including forecasts for subscribers. This country databook contains high-level insights into Australia digital diabetes management market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account